# First-in-Human Study of ICT01 in Patients With Advanced Cancer

Source: https://onco.cc/trials/nct04243499/  
OnCo record `nct04243499` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IV ICT01 in advanced solid tumours, run by ImCheck Therapeutics, an Ipsen company, active and no longer recruiting.

## Summary

First-in-Human Study of ICT01 in Patients With Advanced Cancer is a phase 1/2 interventional study registered as NCT04243499 by ImCheck Therapeutics, an Ipsen company, with 293 participants enrolled, started 2020-03-05 and due to reach its primary completion in 2027-10-15. Interventions recorded: IV ICT01.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04243499
- Phase: 1/2
- Setting: A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
- Sponsor: ImCheck Therapeutics, an Ipsen company
- Enrolled: 293

## Sources

- ClinicalTrials.gov NCT04243499: https://clinicaltrials.gov/study/NCT04243499

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct04243499.json